Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{76958f0d07f6433c9c8d65831b2793a1,
title = "Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use",
abstract = "Background: To our knowledge, disease burden of atopic dermatitis (AD) as number of days with symptoms and medical treatment has never been studied as measure of severity. Objectives: To investigate risk factors for AD burden in the first 3 years of life. Methods: The Copenhagen Prospective Studies on Asthma in Childhood 2010 included 700 children. AD burden was assessed by daily diary entries with information on AD and steroid days measuring 18 possible heritable, prenatal, and postnatal environmental exposures. Results: The children with AD had a median (interquartile range) of 136 symptom days (61-294 days) and 72 steroid days (27-145 days) during the first 3 years of life, with the highest disease burden in the second year of life. The multivariable risk factor analysis showed that maternal AD and childhood allergic sensitization were associated with a higher number of AD days and maternal AD, filaggrin mutation, and allergic sensitization were associated with a higher number of steroid days. Limitations: Participants with a personal interest in atopic diseases could be more likely to participate. Conclusion: Children's burden of AD, assessed quantitatively as AD and steroid days, demonstrated positive associations with maternal AD, filaggrin mutation, and early-life allergic sensitization, with the highest disease burden in the second year of life. ",
keywords = "atopic dermatitis, burden of disease, corticosteroids, eczema severity, filaggrin, pediatrics",
author = "Ruge, {Iben Frier} and Sunna Thorsteinsd{\'o}ttir and Sarah N{\o}rgaard and Chawes, {Bo L} and Klaus B{\o}nnelykke and Jakob Stokholm and Hans Bisgaard",
note = "Copyright {\textcopyright} 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/j.jaad.2020.09.038",
language = "English",
volume = "84",
pages = "725--734",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby, Inc",
number = "3",

}

RIS

TY - JOUR

T1 - Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use

AU - Ruge, Iben Frier

AU - Thorsteinsdóttir, Sunna

AU - Nørgaard, Sarah

AU - Chawes, Bo L

AU - Bønnelykke, Klaus

AU - Stokholm, Jakob

AU - Bisgaard, Hans

N1 - Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - Background: To our knowledge, disease burden of atopic dermatitis (AD) as number of days with symptoms and medical treatment has never been studied as measure of severity. Objectives: To investigate risk factors for AD burden in the first 3 years of life. Methods: The Copenhagen Prospective Studies on Asthma in Childhood 2010 included 700 children. AD burden was assessed by daily diary entries with information on AD and steroid days measuring 18 possible heritable, prenatal, and postnatal environmental exposures. Results: The children with AD had a median (interquartile range) of 136 symptom days (61-294 days) and 72 steroid days (27-145 days) during the first 3 years of life, with the highest disease burden in the second year of life. The multivariable risk factor analysis showed that maternal AD and childhood allergic sensitization were associated with a higher number of AD days and maternal AD, filaggrin mutation, and allergic sensitization were associated with a higher number of steroid days. Limitations: Participants with a personal interest in atopic diseases could be more likely to participate. Conclusion: Children's burden of AD, assessed quantitatively as AD and steroid days, demonstrated positive associations with maternal AD, filaggrin mutation, and early-life allergic sensitization, with the highest disease burden in the second year of life.

AB - Background: To our knowledge, disease burden of atopic dermatitis (AD) as number of days with symptoms and medical treatment has never been studied as measure of severity. Objectives: To investigate risk factors for AD burden in the first 3 years of life. Methods: The Copenhagen Prospective Studies on Asthma in Childhood 2010 included 700 children. AD burden was assessed by daily diary entries with information on AD and steroid days measuring 18 possible heritable, prenatal, and postnatal environmental exposures. Results: The children with AD had a median (interquartile range) of 136 symptom days (61-294 days) and 72 steroid days (27-145 days) during the first 3 years of life, with the highest disease burden in the second year of life. The multivariable risk factor analysis showed that maternal AD and childhood allergic sensitization were associated with a higher number of AD days and maternal AD, filaggrin mutation, and allergic sensitization were associated with a higher number of steroid days. Limitations: Participants with a personal interest in atopic diseases could be more likely to participate. Conclusion: Children's burden of AD, assessed quantitatively as AD and steroid days, demonstrated positive associations with maternal AD, filaggrin mutation, and early-life allergic sensitization, with the highest disease burden in the second year of life.

KW - atopic dermatitis

KW - burden of disease

KW - corticosteroids

KW - eczema severity

KW - filaggrin

KW - pediatrics

UR - http://www.scopus.com/inward/record.url?scp=85099135588&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.09.038

DO - 10.1016/j.jaad.2020.09.038

M3 - Journal article

C2 - 32950548

VL - 84

SP - 725

EP - 734

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 3

ER -

ID: 61273841